NKT-2152 is under clinical development by NiKang Therapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NKT-2152’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NKT-2152 overview
NKT-2152 under development for the treatment of advanced metastatic clear cell renal cell carcinoma and hepatocellular carcinoma. It acts by targeting hypoxia-inducible factor 2alpha (HIF-2alpha). It is administered through oral route.
NiKang Therapeutics overview
NiKang Therapeutics (NKT) is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NKT is headquartered in Wilmington, Delaware, the US.
For a complete picture of NKT-2152’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.